Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques

mAbs

Volumn 5, Issue 5, 2013, Pages 699-710

  Ayoub, Daniel ^a   Jabs, Wolfgang ^b   Resemann, Anja ^b   Evers, Waltraud ^b   Evans, Catherine ^b   Main, Laura ^b   Baessmann, Carsten ^b   Wagner Rousset, Elsa ^a   Suckau, Detlev ^b   Beck, Alain ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b BRUKER DALTONIK GMBH   (Germany)

Author keywords

Biosimilar; Cetuximab; Glycosylation; Mass spectrometry; Sequence

Indexed keywords

CETUXIMAB; GLYCAN;

ARTICLE; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; GLYCOSYLATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BIOSIMILAR; CETUXIMAB; GLYCOSYLATION; MASS SPECTROMETRY; SEQUENCE;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING SITES; BIOSIMILAR PHARMACEUTICALS; GLYCOSYLATION; HUMANS; MOLECULAR SEQUENCE DATA; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84883860531     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.25423     Document Type: Article

References (36)

1. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747
2. Beck A. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs 2011; 3:107-10; PMID:21285536; http://dx.doi.org/10.4161/mabs.3.2.14785
3. Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637-46; PMID:22510259; http://dx.doi. org/10.1021/ac3002885
4. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. MAbs 2010; 2:613-24; PMID:20818176; http://dx.doi.org/10.4161/mabs.2.6.13333
5. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs 2011; 3:209-17; PMID:21441787; http://dx.doi.org/10.4161/mabs.3.2.15005
6. Kálmán-Szekeres Z, Olajos M, Ganzler K. Analytical aspects of biosimilarity issues of protein drugs. J Pharm Biomed Anal 2012; 69:185-95; PMID:22633839; http://dx.doi.org/10.1016/j.jpba.2012.04.037
7. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26:985-90; PMID:18779806; http://dx.doi.org/10.1038/nbt0908-985
8. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood 2012; 120:5111-7; PMID:23093622; http://dx.doi.org/10.1182/blood-2012-04-425744
9. Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, et al. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2010; 2:2; PMID:20458189
10. Beck A, Diemer H, Ayoub D, Debaene F, Wagner-Rousset E, Carapito C, et al. Trends in biosimilar antibody and Fc-fusion protein analytical characterization. Trends Analyt Chem 2013; In press; http://dx.doi. org/10.1016/j.trac.2013.02.014.
11. Tan Q, Guo Q, Fang C, Wang C, Li B, Wang H, et al. Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products. MAbs 2012; 4:761-74; PMID:23032066; http://dx.doi.org/10.4161/mabs.22276
12. Goetze AM, Schenauer MR, Flynn GC. Assessing monoclonal antibody product quality attribute criticality through clinical studies. MAbs 2010; 2:500-7; PMID:20671426; http://dx.doi.org/10.4161/mabs.2.5.12897
13. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10:101-11; PMID:21283105; http://dx.doi.org/10.1038/nrd3365
14. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012; 1253:170-80; PMID:22288459; http://dx.doi.org/10.1111/j. 1749-6632.2011.06305.x
15. Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier- Cianférani S. Characterization of therapeutic antibodies and related products. Anal Chem 2013; 85:715-36; PMID:23134362; http://dx.doi. org/10.1021/ac3032355
16. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11; PMID:15837620; http://dx.doi. org/10.1016/j.ccr.2005.03.003
17. Dubois M, Fenaille F, Clement G, Lechmann M, Tabet JC, Ezan E, et al. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal Chem 2008; 80:1737-45; PMID:18225864; http://dx.doi.org/10.1021/ac7021234
18. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose. N Engl J Med 2008; 358:1109-17; PMID:18337601; http://dx.doi.org/10. 1056/NEJMoa074943
19. Suckau D, Resemann A. T3-sequencing: targeted characterization of the N- and C-termini of undigested proteins by mass spectrometry. Anal Chem 2003; 75:5817-24; PMID:14588022; http://dx.doi. org/10.1021/ac034362b
20. Hardouin J. Protein sequence information by matrixassisted laser desorption/ionization in-source decay mass spectrometry. Mass Spectrom Rev 2007; 26:672-82; PMID:17492750; http://dx.doi.org/10.1002/mas.20142
21. Sundaram S, Matathia A, Qian J, Zhang J, Hsieh MC, Liu T, et al. An innovative approach for the characterization of the isoforms of a monoclonal antibody product. MAbs 2011; 3:505-12; PMID:22123057; http://dx.doi.org/10.4161/ mabs.3.6.18090
22. Janin-Bussat MC, Tonini L, Huillet C, Colas O, Klinguer-Hamour C, Corvaïa N, et al. Cetuximab Fab and Fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry. Methods Mol Biol 2013; 988:93-113; PMID:23475716; http://dx.doi. org/10.1007/978-1-62703-327-5-7
23. Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 2007; 364:8-18; PMID:17362871; http://dx.doi.org/10.1016/j. ab.2007.01.023
24. Zhang Z, Pan H, Chen X. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom Rev 2009; 28:147-76; PMID:18720354; http://dx.doi.org/10.1002/mas.20190
25. Chevreux G, Tilly N, Bihoreau N. Fast analysis of recombinant monoclonal antibodies using IdeS proteolytic digestion and electrospray mass spectrometry. Anal Biochem 2011; 415:212-4; PMID:21596014; http://dx.doi.org/10.1016/j.ab. 2011.04.030
26. Beavis RC. Chemical mass of carbon in proteins. Anal Chem 1993; 65:496-7; http://dx.doi.org/10.1021/ac00052a030
27. Takayam MN. Cα bond cleavage of the peptide backbone via hydrogen abstraction. J Am Soc Mass Spectrom 2001; 12:1044-9; http://dx.doi.org/10.1016/ S1044-0305(01)00289-6
28. Demeure K, Quinton L, Gabelica V, De Pauw E. Rational selection of the optimum MALDI matrix for top-down proteomics by in-source decay. Anal Chem 2007; 79:8678-85; PMID:17939742; http://dx.doi. org/10.1021/ac070849z
29. Resemann A, Wunderlich D, Rothbauer U, Warscheid B, Leonhardt H, Fuchser J, et al. Top-down de Novo protein sequencing of a 13.6 kDa camelid single heavy chain antibody by matrix-assisted laser desorption ionization-time-of-flight/ time-of-flight mass spectrometry. Anal Chem 2010; 82:3283-92; PMID:20329751; http://dx.doi.org/10.1021/ac1000515
30. Wang X, Singh SK, Kumar S. Potential aggregationprone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis. Pharm Res 2010; 27:1512-29; PMID:20422267; http://dx.doi. org/10.1007/s11095-010-0143-5
31. Wuhrer M, Catalina MI, Deelder AM, Hokke CH. Glycoproteomics based on tandem mass spectrometry of glycopeptides. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 849:115-28; PMID:17049937; http://dx.doi.org/10.1016/j.jchromb. 2006.09.041
32. Rapp U, Resemann A, Mayer-Posner FJ, Schäfer W, Feichtinger K. The fragmentation behavior of glycopeptides using the PSD technique. In: Townsend A, Hotchkiss A, eds. Techniques in Glycobiology. New York: Marcel Dekker Inc., 1997:53-65.
33. Senko M, Beu S, McLaffertycor F. Determination of monoisotopic masses and ion populations for large biomolecules from resolved isotopic distributions. J Am Soc Mass Spectrom 1995; 6:229-33; http://dx.doi. org/10.1016/1044-0305(95) 00017-8
34. Tsybin YO, Fornelli L, Stoermer C, Luebeck M, Parra J, Nallet S, et al. Structural analysis of intact monoclonal antibodies by electron transfer dissociation mass spectrometry. Anal Chem 2011; 83:8919-27; PMID:22017162; http://dx.doi.org/10.1021/ac201293m
35. Koster C. Mass spectrometry method for accurate mass determination of unknown ions. US Patent 6188064, 2001.
36. Ranzinger R, Herget S, von der Lieth CW, Frank M. GlycomeDB-a unified database for carbohydrate structures. Nucleic Acids Res 2011; 39(Database issue):D373-6; PMID:21045056; http://dx.doi. org/10.1093/nar/gkq1014